Fortress Biotech, Inc. APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition
Fortress Biotech, Inc. (FBIO) reported APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition of $2.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition · last filed 2026-08-13
- Fortress Biotech, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-06-30 was $2.88M, a 82.86% decline year-over-year.
- Fortress Biotech, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2026-03-31 was $1.76M, a 72.08% decline year-over-year.
- Fortress Biotech, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-12-31 was $2.46M, a 84.81% decline year-over-year.
- Fortress Biotech, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for the quarter ending 2025-09-30 was $3.20M, a 51.36% decline year-over-year.
- Fortress Biotech, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2025 was $28.74M, a 11.89% decline from fiscal 2024.
- Fortress Biotech, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2024 was $32.62M, a 91.55% increase from fiscal 2023.
- Fortress Biotech, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2023 was $17.03M, a 25.92% decline from fiscal 2022.
- Fortress Biotech, Inc. apic, share-based payment arrangement, espp, increase for cost recognition for fiscal 2022 was $22.99M, a 17.97% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, ESPP, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.88M 10-Q · filed 2026-08-13 | $4.63M 10-Q · filed 2026-08-13 | $7.09M derived: sum of 3 quarters · filed 2026-08-13 | $10.29M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $1.76M 10-Q · filed 2026-05-14 | $4.21M derived: sum of 2 quarters · filed 2026-05-14 | $7.41M derived: sum of 3 quarters · filed 2026-05-14 | $24.20M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $2.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $5.66M derived: sum of 2 quarters · filed 2026-03-31 | $22.45M derived: sum of 3 quarters · filed 2026-08-13 | $28.74M 10-K · filed 2026-03-31 | |||
| 2025-09-30 | $3.20M 10-Q · filed 2025-11-14 | $19.99M derived: sum of 2 quarters · filed 2026-08-13 | $26.28M 10-Q · filed 2025-11-14 | $42.47M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $16.79M 10-Q · filed 2026-08-13 | $23.08M 10-Q · filed 2026-08-13 | $39.27M derived: sum of 3 quarters · filed 2026-08-13 | $45.84M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $6.29M 10-Q · filed 2026-05-14 | $22.48M derived: sum of 2 quarters · filed 2026-05-14 | $29.05M derived: sum of 3 quarters · filed 2026-05-14 | $34.05M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $16.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $22.76M derived: sum of 2 quarters · filed 2026-03-31 | $27.76M derived: sum of 3 quarters · filed 2026-03-31 | $32.62M 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $6.57M 10-Q · filed 2025-11-14 | $11.57M derived: sum of 2 quarters · filed 2025-11-14 | $16.43M 10-Q · filed 2025-11-14 | $20.13M derived: sum of 4 quarters · filed 2025-11-14 | |||
| 2024-06-30 | $5.00M 10-Q · filed 2025-08-14 | $9.86M 10-Q · filed 2025-08-14 | $13.56M derived: sum of 3 quarters · filed 2025-08-14 | $17.94M derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $4.86M 10-Q · filed 2025-05-15 | $8.56M derived: sum of 2 quarters · filed 2025-05-15 | $12.94M derived: sum of 3 quarters · filed 2025-05-15 | $17.16M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $8.08M derived: sum of 2 quarters · filed 2025-03-31 | $12.30M derived: sum of 3 quarters · filed 2025-03-31 | $17.03M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $4.38M 10-Q · filed 2024-11-14 | $8.59M derived: sum of 2 quarters · filed 2024-11-14 | $13.32M 10-Q · filed 2024-11-14 | $18.83M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $4.22M 10-Q · filed 2024-08-13 | $8.95M 10-Q · filed 2024-08-13 | $14.45M derived: sum of 3 quarters · filed 2024-08-13 | $21.29M derived: sum of 4 quarters · filed 2024-08-13 | |||
| 2023-03-31 | $4.73M 10-Q · filed 2024-05-15 | $10.24M derived: sum of 2 quarters · filed 2024-05-15 | $17.07M derived: sum of 3 quarters · filed 2024-05-15 | $22.16M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $5.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $12.34M derived: sum of 2 quarters · filed 2024-03-28 | $17.42M derived: sum of 3 quarters · filed 2024-03-28 | $22.99M 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $6.84M 10-Q · filed 2023-11-14 | $11.92M derived: sum of 2 quarters · filed 2023-11-14 | $17.48M 10-Q · filed 2023-11-14 | $24.52M derived: sum of 4 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $5.08M 10-Q · filed 2023-08-14 | $10.64M 10-Q · filed 2023-08-14 | $17.68M derived: sum of 3 quarters · filed 2023-08-14 | $22.01M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | $5.56M 10-Q · filed 2023-05-15 | $12.60M derived: sum of 2 quarters · filed 2023-05-15 | $16.93M derived: sum of 3 quarters · filed 2023-05-15 | $21.28M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $11.36M derived: sum of 2 quarters · filed 2023-03-31 | $15.71M derived: sum of 3 quarters · filed 2023-03-31 | $19.49M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $4.33M 10-Q · filed 2022-11-14 | $8.68M derived: sum of 2 quarters · filed 2022-11-14 | $12.45M 10-Q · filed 2022-11-14 | $15.58M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | $4.35M 10-Q · filed 2022-08-11 | $8.12M 10-Q · filed 2022-08-11 | $11.26M derived: sum of 3 quarters · filed 2022-08-11 | $14.43M derived: sum of 4 quarters · filed 2022-08-11 | |||
| 2021-03-31 | $3.77M 10-Q · filed 2022-05-12 | $6.91M derived: sum of 2 quarters · filed 2022-05-12 | $10.08M derived: sum of 3 quarters · filed 2022-05-12 | $13.82M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $3.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $6.30M derived: sum of 2 quarters · filed 2022-03-28 | $10.05M derived: sum of 3 quarters · filed 2022-03-28 | $13.45M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $3.17M 10-Q · filed 2021-11-15 | $6.92M derived: sum of 2 quarters · filed 2021-11-15 | $10.32M 10-Q · filed 2021-11-15 | $13.08M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $3.75M 10-Q · filed 2021-08-16 | $7.15M 10-Q · filed 2021-08-16 | $9.91M derived: sum of 3 quarters · filed 2021-08-16 | $13.65M derived: sum of 4 quarters · filed 2021-08-16 | |||
| 2020-03-31 | $3.40M 10-Q · filed 2021-05-17 | $6.17M derived: sum of 2 quarters · filed 2021-05-17 | $9.91M derived: sum of 3 quarters · filed 2021-05-17 | $13.28M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $2.77M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-09 | $6.51M derived: sum of 2 quarters · filed 2021-04-09 | $9.88M derived: sum of 3 quarters · filed 2021-04-09 | $13.19M 10-K/A · filed 2021-04-09 | |||
| 2019-09-30 | $3.74M 10-Q · filed 2020-11-09 | $7.11M derived: sum of 2 quarters · filed 2020-11-09 | $10.42M 10-Q · filed 2020-11-09 | $13.39M derived: sum of 4 quarters · filed 2020-11-09 | |||
| 2019-06-30 | $3.37M 10-Q · filed 2020-08-10 | $6.68M 10-Q · filed 2020-08-10 | $9.65M derived: sum of 3 quarters · filed 2020-08-10 | $13.75M derived: sum of 4 quarters · filed 2020-08-10 | |||
| 2019-03-31 | $3.31M 10-Q · filed 2020-05-11 | $6.28M derived: sum of 2 quarters · filed 2020-05-11 | $10.37M derived: sum of 3 quarters · filed 2020-05-11 | $13.53M derived: sum of 4 quarters · filed 2020-05-11 | |||
| 2018-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $7.07M derived: sum of 2 quarters · filed 2020-03-16 | $10.22M derived: sum of 3 quarters · filed 2020-03-16 | $15.01M 10-K · filed 2020-03-16 | |||
| 2018-09-30 | $4.10M 10-Q · filed 2019-11-12 | $7.25M derived: sum of 2 quarters · filed 2019-11-12 | $12.04M 10-Q · filed 2019-11-12 | $13.65M 10-Q · filed 2018-11-09 | $13.40M derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2018-06-30 | $3.15M 10-Q · filed 2019-08-09 | $7.95M 10-Q · filed 2019-08-09 | $8.62M 10-Q · filed 2018-08-09 | $9.30M derived: sum of 3 quarters · filed 2019-08-09 | $13.61M derived: sum of 4 quarters · filed 2019-08-09 | ||
| 2018-03-31 | $4.79M 10-Q · filed 2019-05-10 | $5.05M 10-Q · filed 2018-05-10 | $6.15M derived: sum of 2 quarters · filed 2019-05-10 | $10.46M derived: sum of 3 quarters · filed 2019-05-10 | $15.27M derived: sum of 4 quarters · filed 2019-05-10 | ||
| 2017-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $5.67M derived: sum of 2 quarters · filed 2019-03-18 | $10.47M derived: sum of 3 quarters · filed 2019-03-18 | $13.40M 10-K · filed 2019-03-18 | |||
| 2017-09-30 | $4.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $9.12M derived: sum of 2 quarters · filed 2017-11-09 | $12.05M 10-Q · filed 2017-11-09 | $15.38M derived: sum of 4 quarters · filed 2017-11-09 | |||
| 2017-06-30 | $4.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $7.74M 10-Q · filed 2017-08-09 | $11.07M derived: sum of 3 quarters · filed 2017-08-09 | ||||
| 2017-03-31 | $2.93M 10-Q · filed 2017-05-10 | $6.26M derived: sum of 2 quarters · filed 2017-05-10 | |||||
| 2016-12-31 | $3.34M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | $12.13M 10-K · filed 2017-03-16 | |||||
| 2016-09-30 | $8.79M 10-Q · filed 2016-11-09 | ||||||
| 2015-12-31 | $14.29M 10-K · filed 2017-03-16 | ||||||
| 2014-12-31 | $5.55M 10-K · filed 2017-03-16 | ||||||
| 2013-12-31 | $5.90M 10-K · filed 2016-03-15 | ||||||
| 2012-12-31 | $3.96M 10-K · filed 2015-03-16 | ||||||
| 2011-12-31 | $903.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $1.47M 10-K · filed 2014-03-14 | |||||
| 2011-09-30 | $566.00K 10-Q · filed 2011-11-14 | ||||||
| 2010-12-31 | $2.33M 10-K · filed 2014-03-14 | ||||||
| 2009-12-31 | $39.00K 10-K · filed 2014-03-14 | ||||||
| 2008-12-31 | $25.00K 10-K · filed 2014-03-14 | ||||||
| 2007-12-31 | $13.00K 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |